ProQR reveals positive results from Phase 1/2 trial of Sepofarsen
Category: #health  By Pankaj Singh  Date: 2019-10-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

ProQR reveals positive results from Phase 1/2 trial of Sepofarsen

Leber congenital amaurosis (LCA) is a very rare eye condition that can be seen in newborn babies. Currently, the disease doesn’t have a permanent therapy, however, many pharma companies are now making some advancements to treat this disease.

ProQR Therapeutics N.V., a biotechnology company based in Netherlands, is one such firm that has recently revealed encouraging top-line findings from the PQ-110-001 study, a dose range finding, first-in-human trial Phase 1/2 trials of sepofarsen (QR-110) in patients suffering from LCA10 (Leber’s congenital amaurosis 10) due to the mutation of p.Cys998X in CEP290 gene.

Speaking on the move, Stephen R. Russell, MD, Principal Investigator, the University of Iowa, said that the trial has established that patients getting sepofarsen showed a clinically meaningful development in vision, meanwhile in a few situations the patient showed a groundbreaking improvement in vision which could be said as life-changing.

As per David Rodman, M.D., Executive Vice President of Research & Development, ProQR, the company is delighted with the reported data from the Phase 1/2 trial, where in LCA10 patients demonstrated a durable and rapid improvement in vision after regular dosage of sepofarsen.

Moreover, the positive data from this trial further strengthens the company’s trust in the design of the Phase 2/3 study, which might act as the primary registration trial for the drug program, adds Rodman

Reportedly, ProQR has also prior made some advancements in this field when it revealed that sepofarsen was cleared for the PRIME (PRIority Medicines) program by the EMA (European Medicines Agency).

Commenting on the approval, Daniel A. de Boer, Chief Executive Officer, ProQR, said that the agency’s decision to provide PRIME access to its therapy further establishes the grueling demand for modern medicine to treat LCA10 patients, which simplifies the rigorous selection process of the therapy.

Furthermore, the company hopes to expand sepofarsen’s reach to patients of LCA10 as soon as possible, he added.

Source Credit: https://ir.proqr.com/news-releases/news-release-details/proqr-announces-positive-top-line-results-phase-12-study



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...